Mérieux Equity Partners

Type

Venture Capital, Private equity

Status

Active

Location

Lyon, France

Total investments

13

Average round size

26M

Portfolio companies

13

Lead investments

3

Exits

1

Stages of investment
Private Equity
Areas of investment
BiotechnologyHealth CareManufacturingMedical DeviceMedicalLife SciencePharmaceuticalVeterinaryClinical TrialsCannabis

Investor highlights

Industry focus
Biotech/Life SciencesMedtech
Stage focus
Seed
Geo focus
AlbaniaAustriaBelgiumBosnia and HerzegovinaBulgaria Show 38 more
Check size
4M — 11M

Discover reliable insights

Find relevant VC investors, identify key contacts and secure funding opportunities.

Investments analytics

Analytics

Total investments
13
Lead investments
3
Exits
1
Investments by industry
  • Biotechnology (8)
  • Health Care (5)
  • Pharmaceutical (3)
  • Life Science (3)
  • Medical (3)
  • Show 11 more
Investments by region
  • France (6)
  • Switzerland (1)
  • Belgium (2)
  • United Kingdom (1)
  • United States (1)
  • Show 1 more
Peak activity year
2022

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.

Quantitative data

Avg. startup age at the time of investment
10
Avg. valuation at time of investment
65M
Group Appearance index
0.92
Avg. company exit year
25

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Latest deals

Company name Deal date Industry Deal stage Deal size Location
Prothea Technologies 09 Apr 2024 Early Stage Venture 14M

Similar funds

By same location

By same geo focus

By doing lead investments

How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.